| Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. | |
| | |
MedLine Citation:
|
PMID: 9218080 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: To compare lansoprazole 30 mg daily with ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. METHODS: In a double-blind, parallel group, randomized, mutlicentre study conducted in 32 general practices in the UK, 213 patients were randomized to receive lansoprazole 30 mg daily, and 219 to receive ranitidine 150 mg b.d., for 4 weeks. All patients had experienced symptoms of reflux-like or ulcer-like dyspepsia on at least 4 of the 7 days prior to the study; 75% had experienced dyspepsia in the past, and 74 of the lansoprazole patients and 77 of the ranitidine patients had documented histories of acid-related disorders, investigating by either radiology or endoscopy. RESULTS: After 2 weeks 55% of the lansoprazole patients and 33% of the ranitidine group were symptom-free (P = 0.001, chi 2 = 7.12) with corresponding 4-week figures of 69% and 44%, respectively (P = 0.001, chi 2 = 18.03). Similar figures were found at both 2 and 4 weeks for daytime and night-time heartburn and epigastric pain scores; in the lansoprazole group, at 4 weeks, 80% of patients were free of daytime heartburn and 81% of night-time epigastric pain, compared with 55% (P = 0.001, chi 2 = 15.44) and 65% (P = 0.01, chi 2 = 6.10) in the ranitidine group. CONCLUSION: Superior symptom relief for patients presenting with ulcer-like and reflux-like symptoms in general practice is provided by lansoprazole 30 mg daily compared with ranitidine 150 mg twice daily. |
| | |
Authors:
|
R H Jones; G Baxter |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Alimentary pharmacology & therapeutics Volume: 11 ISSN: 0269-2813 ISO Abbreviation: Aliment. Pharmacol. Ther. Publication Date: 1997 Jun |
Date Detail:
|
Created Date: 1997-07-29 Completed Date: 1997-07-29 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8707234 Medline TA: Aliment Pharmacol Ther Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 541-6 Citation Subset: IM |
Affiliation:
|
Department of General Practice, UMDS (Guy's and St Thomas's), London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
2-Pyridinylmethylsulfinylbenzimidazoles Adolescent Adult Aged Aged, 80 and over Anti-Infective Agents / therapeutic use* Anti-Ulcer Agents / therapeutic use* Double-Blind Method Drug Therapy, Combination Dyspepsia / drug therapy* Humans Middle Aged Omeprazole / analogs & derivatives*, therapeutic use Ranitidine / therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Infective Agents; 0/Anti-Ulcer Agents; 103577-45-3/lansoprazole; 66357-35-5/Ranitidine; 73590-58-6/Omeprazole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and a...
Next Document: Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome.